SCHEMBL20401331

SCHEMBL20401331

COCc1cccc(Cn2cc(-c3cc(-c4cccc(C#N)c4)nc(NC(=O)C4CCCO4)n3)nn2)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.38
▸ NPC1 O15118 5/20 0.38
▸ HPGD P15428 4/20 0.38
▸ HSD17B10 Q99714 3/20 0.38
▸ MAPT P10636 2/20 0.38
▸ USP30 Q70CQ3 4/20 0.36
▸ LMNA P02545 3/20 0.36
▸ KDM4E B2RXH2 3/20 0.36
▸ SMN1; SMN2 Q16637 3/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ ADORA2A P29274 3/20 0.36
▸ ADORA1 P30542 2/20 0.36
▸ ADORA3 P0DMS8 1/20 0.36
▸ RAB9A P51151 3/20 0.36
▸ MAPK1 P28482 2/20 0.36
▸ TSHR P16473 1/20 0.36
▸ ADORA2B P29275 2/20 0.35
▸ POLB P06746 1/20 0.35
▸ MTOR P42345 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30401911 1.00 ALDH1A1 (0.38) ALDH1A1NPC1HPGDHSD17B10MAPT
SCHEMBL30401927 0.98 ALDH1A1 (0.36) ALDH1A1NPC1HPGDHSD17B10MAPT
SCHEMBL20401393 0.98 ALDH1A1 (0.36) ALDH1A1NPC1HPGDHSD17B10MAPT
SCHEMBL20436674 0.93 ALDH1A1 (0.40) ALDH1A1NPC1HPGDHSD17B10MAPT
SCHEMBL20436675 0.91 ALDH1A1 (0.38) ALDH1A1NPC1HPGDHSD17B10MAPT
SCHEMBL30400427 0.86 ADORA2A (0.41) ADORA2AADORA1ADORA3ADORA2BCDC7
SCHEMBL20400314 0.86 ADORA2A (0.41) ADORA2AADORA1ADORA3ADORA2BCDC7
SCHEMBL30401320 0.85 CDC7 (0.41) ADORA2AADORA1ADORA3ADORA2BCDC7
SCHEMBL20401421 0.85 CDC7 (0.41) ADORA2AADORA1ADORA3ADORA2BCDC7
SCHEMBL20401436 0.83 ADORA2A (0.41) ADORA2AADORA1ADORA2BCDC7DAPK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12195447-B2 Azolopyrimidine for the treatment of cancer-related disorders ARCUS BIOSCIENCES, INC. (US) 2025-01-14 — — US disclosed
EP-4310082-A2 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS Arcus Biosciences, Inc. (US) 2024-01-24 — — EP disclosed
EP-4310082-A2 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS Arcus Biosciences, Inc. (US) 2024-01-24 — — EP disclosed
CN-116768859-A Azolopyrimidines for the treatment of cancer related disorders 艾库斯生物科学有限公司 2023-09-19 — — CN disclosed
EP-3570844-B1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ARCUS BIOSCIENCES INC (US) 2023-09-06 — — EP disclosed
EP-3570844-B1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ARCUS BIOSCIENCES INC (US) 2023-09-06 — — EP disclosed
CN-110214012-B Azolopyrimidines for the treatment of cancer related disorders 艾库斯生物科学有限公司 2023-05-09 — — CN disclosed
US-20220144808-A1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ARCUS BIOSCIENCES, INC. 2022-05-12 — — US disclosed
US-20220144808-A1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ARCUS BIOSCIENCES, INC. 2022-05-12 — — US disclosed
US-11072597-B2 Azolopyrimidine for the treatment of cancer-related disorders ARCUS BIOSCIENCES, INC. 2021-07-27 — — US disclosed
US-11072597-B2 Azolopyrimidine for the treatment of cancer-related disorders ARCUS BIOSCIENCES, INC. 2021-07-27 — — US disclosed
US-20210101880-A1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ARCUS BIOSCIENCES, INC. 2021-04-08 — — US disclosed
US-20210101880-A1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ARCUS BIOSCIENCES, INC. 2021-04-08 — — US disclosed
US-10399962-B2 Azolopyrimidine for the treatment of cancer-related disorders ARCUS BIOSCIENCES, INC. (US) 2019-09-03 — — US disclosed
US-10399962-B2 Azolopyrimidine for the treatment of cancer-related disorders ARCUS BIOSCIENCES, INC. (US) 2019-09-03 — — US disclosed
US-20180215730-A1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ARCUS BIOSCIENCES, INC. 2018-08-02 — — US disclosed
US-20180215730-A1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ARCUS BIOSCIENCES, INC. 2018-08-02 — — US disclosed
US-20180215730-A1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ARCUS BIOSCIENCES, INC. 2018-08-02 — — US disclosed
WO-2018136700-A1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ARCUS BIOSCIENCES, INC. (US) 2018-07-26 — — WO disclosed
WO-2018136700-A1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ARCUS BIOSCIENCES, INC. (US) 2018-07-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220144808-A1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ADORA2A, ADORA2B, ADORA1 ALDH1A1 679/4885NPC1 3259/4885HPGD 987/4885
US-11072597-B2 Azolopyrimidine for the treatment of cancer-related disorders ADORA2A, ADORA2B, ADORA1 ALDH1A1 679/4885NPC1 3259/4885HPGD 987/4885
US-12195447-B2 Azolopyrimidine for the treatment of cancer-related disorders ADORA2A, ADORA2B, ADORA1 ALDH1A1 679/4885NPC1 3259/4885HPGD 987/4885
US-20180215730-A1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ADORA2A, ADORA2B, ADORA1 ALDH1A1 679/4885NPC1 3259/4885HPGD 987/4885
US-10399962-B2 Azolopyrimidine for the treatment of cancer-related disorders ADORA2A, ADORA2B, ADORA1 ALDH1A1 679/4885NPC1 3259/4885HPGD 987/4885
US-20210101880-A1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ADORA2A, ADORA2B, ADORA1 ALDH1A1 679/4885NPC1 3259/4885HPGD 987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback